Twelve-Month ROQ Outcomes in 1,410 Occupational-Skin Patients
Doctor’s Notes · Life in Motion · Evidence Review
Editorial disclosure: The featured image is an AI-created illustration of a fictional work or daily-life scene. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.
Reader question: What changed over 12 months after a multidisciplinary prevention program in 1,410 patients?
Study snapshot
| Study element | Reported detail |
|---|---|
| Population | 1,788 German patients with severe occupational skin disease entered the multicenter ROQ tertiary-prevention cohort; 1,410 were available at 12-month follow-up. |
| Design | Prospective uncontrolled multicenter before-and-after cohort following a three-week inpatient interdisciplinary prevention program. |
| Comparator | Each participant’s admission measures were compared with 12-month outcomes; there was no randomized usual-care control. |
| Timepoint | Admission, inpatient treatment and 12 months after discharge. |
| Key result | The 12-month response rate was 78.9% (1,410 of 1,788). The authors reported sustained improvement in clinical severity and patient-reported outcomes after the integrated program, while the uncontrolled design prevents isolating which component produced change. |
| Funding/conflict context | The program was embedded in the German social accident-insurance prevention system; the indexed abstract does not provide complete conflict detail. It did not test Dr. Arsy #003. |
What was actually measured?
The 12-month response rate was 78.9% (1,410 of 1,788). The authors reported sustained improvement in clinical severity and patient-reported outcomes after the integrated program, while the uncontrolled design prevents isolating which component produced change.
Large multicenter follow-up supports real-world feasibility and durability, not randomized comparative efficacy.
The denominator defines the scope. A patch-test clinic, selected case series, compensation registry, online questionnaire, workplace cohort and general-population survey answer different questions. A percentage from one cannot be silently transferred to the others.
What the result does not prove
No concurrent control, attrition, regression to the mean, simultaneous interventions and insurance-system selection limit causal attribution.
Association, timing and biological plausibility can strengthen an occupational interpretation, but observational evidence cannot automatically establish individual causation. Referral patterns, reporting practices, task mix, protective equipment, nonwork exposures and access to care may all change an estimate.
A PubMed record is a bibliographic source. PubMed indexing is not NIH endorsement of the authors' conclusions, this interpretation or any product.
Exposure detail matters more than the job label
Workers with the same title can handle different materials for different durations. Useful documentation identifies the exact product or process, the route of contact, glove or PPE material, wetness, friction, heat, dust, splash potential, frequency and how symptoms change away from the task.
A symptom survey can identify a pattern, a clinical examination can refine the differential diagnosis, and patch testing can identify delayed sensitization. None of those steps alone proves that a workplace material caused an individual condition. Clinical relevance still requires a credible exposure and time course.
Questions worth recording
- Which task, product, glove, tool, metal, resin, cleanser, food, plant, dust or surface came before symptoms?
- Where did the change begin, and did it improve on days away or after a process or PPE change?
- How often were hands wet, washed, disinfected, occluded, rubbed, heated or exposed to cold?
- Were labels, ingredient information and safety-data sheets reviewed with occupational health?
- Did the problem affect dexterity, sleep, pace, attendance, work quality or safety?
Prevention comes before cosmetic care
Substitution, closed systems, local exhaust, splash control, safer cleaning methods, training and correctly selected protective equipment address exposure at its source. Gloves are not automatically protective: material, fit, breakthrough time, sweating, reuse and rubber accelerators all matter.
Do not deliberately place workplace products on skin to test a theory. Persistent, recurrent or spreading symptoms, drainage, fever, breathing symptoms, severe pain, rapidly worsening redness or major loss of function warrant professional evaluation.
Primary research and guidance
- Primary research record: PubMed PMID 23046085
- NIOSH: occupational skin exposure
- NIAMS: atopic dermatitis
- American Academy of Dermatology: eczema skin care
Where Dr. Arsy #003 fits
Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003. Its findings do not show that #003 treats, cures or prevents eczema, relieves pain or itch, neutralizes workplace chemicals, is appropriate for every person, or provides pediatric or 24-hour efficacy.
Continue the evidence series
- Occupational-Dermatosis Notifications Across 4,710 Brazilian Cases
- Workplace-Irritant Assessment in 316 Suspected Hand-Dermatitis Patients
- Self-Reported Dermatitis in 578 Large-Scale Khat-Farm Workers
- Occupational Hand Dermatitis in 164 Taipei Clinic Patients
Evidence note: This educational article separates reported findings from interpretation. It is not a diagnosis, treatment recommendation or workplace-safety determination.